AKN-028 acetate is a novel, potent, and orally active tyrosine kinase (TK) inhibitor. It specifically targets FMS-like receptor tyrosine kinase 3 (FLT3) with an IC50 value of 6 nM. This compound inhibits FLT3 autophosphorylation and induces a dose-dependent cytotoxic response. It also induces apoptosis through the activation of caspase 3, making it suitable for research in acute myeloid leukemia (AML).
- Potent and orally active tyrosine kinase inhibitor.
- Targets FLT3 with high specificity (IC50 = 6 nM).
- Induces dose-dependent cytotoxic response.
- Activates caspase 3, leading to apoptosis.
- Useful for acute myeloid leukemia (AML) research.